Bellerophon Therapeutics, Inc. (BLPH)
OTCMKTS
· Delayed Price · Currency is USD
0.0120
-0.0041 (-25.47%)
Inactive · Last trade price
on Dec 18, 2024
Bellerophon Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
Cash & Equivalents | 4.38 | 6.92 | 24.74 | 47.56 | 9.87 | 16.65 | Upgrade
|
Cash & Short-Term Investments | 4.38 | 6.92 | 24.74 | 47.56 | 9.87 | 16.65 | Upgrade
|
Cash Growth | -61.28% | -72.01% | -47.99% | 381.64% | -40.68% | -47.69% | Upgrade
|
Prepaid Expenses | 0.49 | 0.23 | 0.62 | 0.42 | 0.41 | 0.65 | Upgrade
|
Restricted Cash | 0.11 | 0.41 | 0.1 | 0.1 | 0.1 | 0.1 | Upgrade
|
Total Current Assets | 4.98 | 7.56 | 25.46 | 48.08 | 10.38 | 17.4 | Upgrade
|
Property, Plant & Equipment | - | 0.19 | 0.93 | 1.67 | 2.43 | 0.66 | Upgrade
|
Other Long-Term Assets | - | 0.19 | 0.49 | 0.49 | 0.3 | 0.3 | Upgrade
|
Total Assets | 4.98 | 7.94 | 26.88 | 50.24 | 13.11 | 18.36 | Upgrade
|
Accounts Payable | 0.61 | 1.23 | 1.19 | 3.73 | 3.11 | 2.76 | Upgrade
|
Accrued Expenses | 0.64 | 3.97 | 3.11 | 6 | 3.82 | 4.78 | Upgrade
|
Current Portion of Leases | - | 0.2 | 0.75 | 0.7 | 0.66 | - | Upgrade
|
Total Current Liabilities | 1.26 | 5.4 | 5.05 | 10.43 | 7.58 | 7.54 | Upgrade
|
Long-Term Leases | - | - | 0.2 | 0.96 | 1.66 | - | Upgrade
|
Other Long-Term Liabilities | - | - | 0 | 0.6 | 0.27 | 6.97 | Upgrade
|
Total Liabilities | 1.26 | 5.4 | 5.26 | 11.99 | 9.52 | 14.5 | Upgrade
|
Common Stock | 0.12 | 0.1 | 0.1 | 0.1 | 0.05 | 0.04 | Upgrade
|
Additional Paid-In Capital | 259.92 | 254.52 | 253.77 | 252.65 | 193.31 | 180.31 | Upgrade
|
Retained Earnings | -256.32 | -252.08 | -232.25 | -214.49 | -189.76 | -176.5 | Upgrade
|
Shareholders' Equity | 3.72 | 2.53 | 21.62 | 38.25 | 3.59 | 3.86 | Upgrade
|
Total Liabilities & Equity | 4.98 | 7.94 | 26.88 | 50.24 | 13.11 | 18.36 | Upgrade
|
Total Debt | - | 0.2 | 0.96 | 1.66 | 2.32 | - | Upgrade
|
Net Cash (Debt) | 4.38 | 6.72 | 23.78 | 45.9 | 7.56 | 16.65 | Upgrade
|
Net Cash Growth | -59.88% | -71.74% | -48.19% | 507.34% | -54.60% | -47.69% | Upgrade
|
Net Cash Per Share | 0.39 | 0.70 | 2.50 | 5.89 | 1.68 | 3.84 | Upgrade
|
Filing Date Shares Outstanding | 12.23 | 10.45 | 9.55 | 9.49 | 6.13 | 4.59 | Upgrade
|
Total Common Shares Outstanding | 12.23 | 9.65 | 9.55 | 9.49 | 4.58 | 3.91 | Upgrade
|
Working Capital | 3.72 | 2.16 | 20.41 | 37.65 | 2.8 | 9.86 | Upgrade
|
Book Value Per Share | 0.30 | 0.26 | 2.26 | 4.03 | 0.78 | 0.99 | Upgrade
|
Tangible Book Value | 3.72 | 2.53 | 21.62 | 38.25 | 3.59 | 3.86 | Upgrade
|
Tangible Book Value Per Share | 0.30 | 0.26 | 2.26 | 4.03 | 0.78 | 0.99 | Upgrade
|
Machinery | - | 2.32 | 2.32 | 2.32 | 2.32 | 2.32 | Upgrade
|
Leasehold Improvements | - | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.